• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis to present at 2016 North American Cystic Fibrosis Conference
Share
Conferences, News, ProteaseTag®

ProAxsis to present at 2016 North American Cystic Fibrosis Conference

October 26, 2016
-
Posted by Webmaster

ProAxsis will this week be presenting new data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference in Orlando, Florida.

The first abstract is entitled “Development of a ProteaseTag® lateral flow device for detection of active neutrophil elastase in the clinic”, and will be presented by Dr Darragh McCafferty between 11.50 and 13.50 on October 27th, 2016 in the New Therapies/Biomarkers session and between 16.00 and 18.00 on October 28th, 2016 in the Special Basic Science Poster Session. This is the first time that data will be presented on the company’s test being developed for rapid measurement of neutrophil elastase at point-of-care.

The second abstract highlights some of the advantages of using the company’s ProteaseTag® technology, based on the selectivity and stability of the inhibitors developed, and is entitled “NE Ultra – A Novel ProteaseTag® for the inhibition and detection of neutrophil elastase in biological samples”. This abstract will also be presented in both the New Therapies/Biomarkers and Special Basic Science Poster sessions.

Dr David Ribeiro, CEO of ProAxsis, said: “This is the 30th annual meeting of the North American Cystic Fibrosis Society, and the organisers expect more than 4000 healthcare professionals to be in attendance.   ProAxsis is delighted to share further information about our ProteaseTag®technology with the cystic fibrosis community at this conference.”

ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.

To learn more about our ProteaseTag® technology, or for further information about measuring active protease biomarkers in biological samples, please visit www.proaxsis.com or contact info@77.104.171.207

October 26, 2016

Related News

Other posts that you should not miss.
News

ProAxsis Limited recognised as Gold Level Innovator by Innovate NI

December 2, 2020
-
Posted by David Ribeiro

ProAxsis (www.proaxsis.com), the Belfast-based protease diagnostics company, is delighted to announce that it has been recognised as …

Read More
December 2, 2020
Posted by David Ribeiro
ProteaseTag®

ProAxsis to showcase ProteaseTag® abstracts at 2017 North American Cystic Fibrosis Conference

October 30, 2017
-
Posted by Webmaster

ProAxsis will be presenting further data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference, …

Read More
October 30, 2017
Posted by Webmaster
News, ProteaseTag®

ProAxsis gains backing of Innovate UK

January 25, 2017
-
Posted by Webmaster

ProAxsis Limited (www.proaxsis.com) is further expanding its ProteaseTag® technology platform, via a project co-funded by the UK’s innovation …

Read More
January 25, 2017
Posted by Webmaster
← PREVIOUS POST
ProAxsis’ ProteaseTag® NE Immunoassay highlighted at BTS 2016
NEXT POST →
ProAxsis receives Royal visit
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis to present at 2016 North American Cystic Fibrosis Conference - ProAxsis